Does Semax affect sleep?
Semax can affect sleep, and whether the effect is beneficial or disruptive largely depends on the dose, the time of administration, individual neurobiology, and the cause of any sleep problems.
No published research has used objective sleep measurement tools – such as polysomnography, a technique that tracks brain waves, eye movements, and muscle activity throughout the night – to directly measure Semax's effects on sleep stages and architecture. Instead, studies provide indirect evidence. Semax's documented effects on serotonin activity, BDNF levels, stress hormone regulation, and brain network activity involve systems closely linked to sleep regulation.
The most significant indirect evidence comes from studies showing that Semax increases serotonin turnover – enhancing its production, release, and degradation – in the striatum [1] and induces anxiolytic and antidepressant effects with chronic administration [2]. Both these effects generally support, rather than disrupt, sleep quality. Serotonin is the direct chemical precursor to melatonin, the hormone that regulates the sleep-wake cycle, and increasing serotonergic activity in specific brain circuits is the same mechanism by which many antidepressant drugs improve sleep in depressed individuals with insomnia.
Semax's inhibitory effects on the HPA axis – including reducing stress-induced corticosterone and preventing adrenal enlargement under chronic stress [3] – also theoretically support better sleep. Elevated cortisol and chronic hyperactivity of the stress system are among the most common biological causes of poor sleep quality.
Does Semax cause insomnia?
Insomnia is not listed as a side effect in any published Semax clinical trials or animal studies. However, anecdotal user reports suggest that taking Semax too late in the day can make it difficult for some individuals to fall asleep.
This is not surprising, given the documented activating effects of Semax on brain networks. A resting-state functional MRI brain imaging study showed measurable changes in default mode network activity as early as 5 minutes after administration of Semax in healthy volunteers [4]. Stimulation of dopaminergic circuits and increased synaptic excitability [5] are features associated with mental activation, not sedation. A compound that sharpens focus, increases neuronal activity, and enhances dopaminergic responses would logically interfere with sleep if taken close to bedtime, even if it does not cause insomnia via a direct pharmacological mechanism.
A chronobiological study of Semax - its effects on biological time rhythms - has shown that chronic administration of Semax normalised the circadian rhythm of locomotor activity in rats. Semax increased the strength of this rhythm and exerted beneficial effects of circadian time rhythm synchronisation [6]. This rhythm-regulating effect suggests that at appropriate doses and times of administration, Semax may support the stability of the circadian rhythm rather than disrupt it.
The same research group found that Semax had varying effects on heart rate variability – an indicator of nervous system balance – depending on whether it was administered in the morning or evening. In the morning, it did not induce significant changes, whereas in the evening, it showed a beneficial effect by reducing sympathetic nervous system activity [7]. This dependence on the time of day suggests a broader biological sensitivity to timing, which likely extends to sleep-related effects.
Does Semax improve sleep or help with sleep disorders?
No published studies have directly investigated Semax as a treatment for insomnia or any specific sleep disorder. However, several documented mechanisms of Semax are relevant to sleep improvement, particularly in the context of poor sleep induced by stress or anxiety.
A study using a chronic unpredictable stress model showed that Semax reversed anhedonia, HPA axis hyperactivity, and reduced hippocampal BDNF levels [3]. These are the same biological disruptions underlying stress-related insomnia. Semax's anti-stress effects may therefore indirectly improve sleep quality in individuals whose poor sleep is driven by chronic stress or anxiety. The reduction in anxiety-like behaviours documented in multiple animal models [2], [8] suggests that individuals using Semax for its anxiolytic effects may experience an indirect improvement in sleep onset and maintenance.
It is important here to compare Semax and Selank. Selank — a related anxiolytic peptide often discussed alongside Semax — has a more sleep-compatible pharmacological profile. Its main mechanism involves reducing anxiety by modulating GABA — the brain's primary inhibitory neurotransmitter — rather than the neuronal activation and cognitive enhancement characteristic of Semax. Users who experience sleep difficulties with Semax sometimes report that switching to Selank in the evening or carefully combining both peptides with appropriate timing better supports their sleep. However, this is based on anecdotal evidence from the community, not clinical research.
Does Semax affect deep sleep or REM sleep?
No published studies have directly measured the effects of Semax on specific sleep stages – including slow-wave sleep (deep sleep) or rapid eye movement (REM) sleep – using polysomnographic methods. This represents a real gap in the scientific literature.
From the available data, it can be inferred that BDNF — which Semax significantly increases — plays an important role in the regulation of REM sleep and sleep-dependent memory consolidation. REM sleep is the stage of sleep during which the brain actively processes and consolidates memories from the day. Studies outside the Semax literature have shown that BDNF promotes REM sleep and that the memory benefits of sleep are partially mediated by BDNF-TrkB signalling during sleep.
If Semax-induced BDNF elevation persists through the sleep period, it could theoretically enhance sleep-dependent memory processing – which would be a beneficial rather than detrimental effect. This reasoning, however, links separate lines of evidence that have not been directly connected in a single study. It should be understood as a plausible hypothesis rather than an established finding.
Semax is best taken in the morning.
The best time to take Semax is generally in the morning or early afternoon, considering its activating pharmacological profile, documented effects on mental alertness and neuronal excitability, and the time-of-day sensitivity observed in chronobiological studies. No controlled human studies have formally compared morning versus evening administration for efficacy or sleep impact. This recommendation stems from pharmacological reasoning rather than direct comparative timing studies – however, it aligns with general principles for any alertness-enhancing compound.
The activating properties of Semax – enhancing dopaminergic response [9], improving glutamatergic synaptic activity [5], and expanding prefrontal cortical activity observed in brain imaging [4] – make late administration logically problematic for individuals sensitive to evening stimulation.
The same properties make a morning dose well suited for the goals most users have for Semax: improved focus, faster learning, enhanced cognitive performance, and mental clarity throughout the workday.
Should Semax be taken before sleep?
Taking Semax immediately before sleep is not recommended for most people due to its activating pharmacological profile.
The discovery that Semax had no effect on heart rate variability in the morning but a significant effect in the evening [7], shows that the body's response to Semax is time-of-day dependent. The same dose elicits qualitatively different physiological effects depending on the time of administration. While the evening effect documented in this study was beneficial in terms of reduced sympathetic nervous system activity, Semax's broader activating effects on the brain – including increased calcium signalling in the hippocampus [10] and enhanced synaptic activity [5] – would likely counteract the dampened brain activity needed to fall asleep.
However, it should be noted that individual variability is considerable, and some users may not experience sleep disturbances with evening use of Semax, particularly at lower doses. Key variables appear to be dose size – higher doses more frequently elicit noticeable stimulation – and individual sensitivity to dopaminergic and serotoninergic activation. Individuals who find it difficult to wind down in the evening, are sensitive to caffeine in the afternoon, or have an anxious tendency in their nervous system should be particularly cautious about taking Semax within several hours of their planned sleep time.
Does the time of day affect the effectiveness of Semax?
Yes — the time of day appears to influence how Semax performs in the body, although this has only been directly researched in the context of cardiac chronobiology, not cognitive performance.
Arushanian and Popov's study clearly showed different heart rate variability responses to Semax depending on whether it was administered in the morning or evening [7]. A chronobiological study of circadian rhythm demonstrated that chronic administration of Semax affected the strength, timing, and spectral characteristics of the daily locomotor activity rhythm [6]. This indicates that Semax interacts with the body's internal timing systems, rather than simply eliciting the same effect regardless of the time of day.
From a practical standpoint, Semax's activating and nootropic effects are most useful and least likely to disrupt sleep when administration coincides with periods of intended cognitive activity. In clinical stroke rehabilitation protocols, Semax has been administered during daytime treatment courses without specific timing concerns being reported in the literature [11], [12], which aligns with daytime use as standard clinical practice.
Should Semax be taken with food?
No published studies have specifically investigated whether food intake affects the pharmacokinetics of Semax — how it is absorbed, distributed, and eliminated from the body — or its pharmacodynamic effects when administered intranasally.
As the intranasal route delivers the peptide directly to the brain via the olfactory pathway, Semax largely bypasses gastrointestinal processing entirely. It does not have to go through the stomach and intestines, nor undergo first-pass metabolism in the liver. This means that the presence or absence of food in the stomach should not significantly alter the amount of Semax reaching the brain, or the speed of this process.
When administered subcutaneously, food intake also does not significantly affect the absorption of the peptide from subcutaneous tissue. Therefore, there is no strong pharmacological reason to combine the timing of nasal or injected Semax administration with meals.
Do Semax and Selank affect sleep when taken together?
Semax and Selank have complementary and partially opposing pharmacological profiles that, with thoughtful timing, may induce an effect more compatible with sleep than Semax used alone. However, no published study has directly examined the effects of this combination on sleep quality, sleep architecture, or insomnia.
Selank is a synthetic heptapeptide developed as an analogue of tuftsin, a naturally occurring immune system peptide. It was created concurrently with Semax at the same Russian Institute of Molecular Genetics. Its main pharmacological profile is anxiolytic – it reduces anxiety – through mechanisms that include modulation of GABA receptors (enhancing the brain's calming signals), inhibition of enkephalinase (prolonging the activity of the body's own natural calming brain peptides called enkephalins), and modulation of pro-inflammatory cytokines [13].
Unlike Semax, which has a more activating and nootropic profile, Selank's primary effect is calming and anxiolytic—without causing sedation or cognitive impairment. In a study of resting-state functional MRI analysing both peptides in the same participants, Selank and Semax induced both common and distinct effects on functional connectivity between the right amygdala—the brain's primary fear and threat detection centre—and surrounding temporal cortex areas [14]. Selank demonstrated a pattern more consistent with emotional dampening.
What is better for sleep - Semax or Selank?
If the goal is to improve sleep, Selank has a more directly sleep-compatible pharmacological profile than Semax and would generally be the better choice of these two peptides. Selank's anxiolytic and GABA-modulating properties directly address the over-excitation of the mind and intrusive thoughts - some of the most common causes of difficulty falling and staying asleep - without the neuronal activation and dopaminergic enhancement that can make Semax disruptive to sleep in the evening.
The enkephalinase inhibitory effect of Selank — which prolongs the activity of the brain's own enkephalins, molecules akin to endorphins that induce sedation and mild mood elevation [13] — also contributes to the calming effect of supporting the brain's readiness for sleep.
It is important to note, however, that this comparison is based on pharmacological reasoning from separate studies of each peptide individually, rather than any direct comparative study of their effects on sleep. Neither peptide has been formally evaluated as a sleep aid in controlled clinical trials, and recommending either specifically for sleep disorders goes beyond what current evidence justifies.
Does the combination of Semax and Selank affect sleep differently than each peptide on its own?
The combination of Semax and Selank is often used in Russian clinical practice and discussed in nootropic communities as a way to balance the activating effects of Semax with the calming properties of Selank — potentially creating a more balanced cognitive and emotional effect than either compound used alone.
In the functional connectivity study, both peptides were investigated in the same 52 healthy participants, allowing for a direct comparison of their individual effects on amygdala-related functional connectivity. The results demonstrated both overlapping and distinct effects, suggesting that their combined use would not simply duplicate the effects of one peptide, but rather elicit an additive combination of separate pharmacological actions [14]. Whether this combination specifically translates to improved sleep has not been investigated.
The theoretical basis for the beneficial influence of the evening combination is straightforward. If Selank is taken in the evening for anxiety reduction and to promote calmness, and Semax is taken solely in the morning for cognitive activation, both peptides essentially function sequentially rather than concurrently. Semax supports daytime cognitive performance; Selank supports evening relaxation and sleep onset. This is a practical timing strategy that many users online describe—however, it needs to be clearly emphasized that this is a user-derived dosing practice, not a clinically validated protocol.
If sleep is a problem, it is best to take Semax and Selank in the morning or early afternoon. Both are stimulants and can interfere with sleep if taken too late in the day.
Based on the pharmacological profiles of both peptides and available indirect evidence, the temporal approach described by many users – though no clinical trial has formally tested it – involves taking Semax in the morning to leverage its cognitive and activating properties during the workday, and reserving Selank for the afternoon or evening, when its anxiolytic and calming effects are most useful in transitioning towards sleep.
This approach utilises Semax's stimulating properties when they are most beneficial, and Selank's calming properties neutralise any residual neuronal activation in the hours before sleep.
Functional connectivity studies examining both peptides were conducted with brain imaging measurements at baseline, 5 minutes, and 20 minutes post-administration [14], confirming that both peptides elicit rapid effects on the central nervous system. This implies that the timing of administration relative to desired effects — and relative to sleep — is of practical importance. Taking Semax a few hours before bed and Selank closer to evening or bedtime is an approach consistent with the pharmacological properties of each compound, even in the absence of a clinical trial specifically substantiating the benefits of this schedule for sleep.
Does the combination of Semax and Selank affect cortisol or the HPA axis?
Both Semax and Selank independently show evidence of suppressing stress responses and reducing HPA axis hyperactivity. This suggests their combination may have complementary anti-stress effects relevant to the cortisol dysregulation that often disrupts sleep.
Semax reversed chronic stress-induced adrenal hypertrophy and lowered corticosterone levels in stressed rats [3], [15]. Selank reduced pro-inflammatory stress markers, including IL-1β, IL-6, and TNF-α, under social stress conditions [13], reflecting anti-stress and anti-inflammatory activity via a different, yet compatible, mechanism.
Elevated evening cortisol — sometimes informally described as being „tired but wired,” where a person feels physically exhausted but can’t switch off their mind — is one of the most common hormonal causes of difficulty falling asleep despite feeling tired. Compounds that reduce the reactivity of the HPA axis without completely suppressing it could theoretically help normalise the natural cortisol rhythm that supports healthy sleep.
However, it must be clearly stated that no study has directly measured cortisol or HPA axis markers in response to the Semax-Selank combination. The effects of combining both compounds on stress hormone regulation have not been directly investigated. The suggestion that this combination may favourably impact HPA axis-related sleep disturbances is based on separate bodies of evidence for the individual effects of each compound – this is a justifiable hypothesis that nevertheless requires direct research before it can be presented as an established finding.
Disclaimer
This article is for educational, informational, and scientific purposes only and should not be interpreted as medical advice, diagnosis, therapeutic recommendation, or a claim about the safety or efficacy of Semax or Selank for the treatment of any medical condition. Both Semax and Selank remain investigational compounds in most countries, including the United States and most European countries, and are not approved by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for the treatment of any medical conditions. They are approved and used clinically in Russia and some Eastern European countries. Most of the evidence presented in this article is derived from preclinical animal studies and a limited number of human clinical trials. Additional well-designed clinical studies are needed to more accurately establish the safety, efficacy, mechanisms of action, and long-term effects of Semax and Selank in humans.
References
[1] Eremin, K. O., Kudrin, V. S., Saransaari, P., Oja, S. S., Grivennikov, I. A., Myasoedov, N. F., & Rayevsky, K. S. (2005). Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochemical Research, 30(12), 1493–1500. https://doi.org/10.1007/s11064-005-8826-8
[2] Vilenskiĭ, D. A., Levitskaia, N. G., Andreeva, L. A., Alfeeva, L. Yu., Kamenskiĭ, A. A., & Miasoedov, N. F. (2007). Effects of chronic Semax administration on exploratory activity and emotional reaction in white rats. Rossiyskiy Fiziologicheskiy Zhurnal imeni I.M. Sechenova, 93(6), 661–669. PMID: 17850024
[3] Inozemtseva, L. S., Yatsenko, K. A., Glazova, N. Yu., Kamensky, A. A., Myasoedov, N. F., Levitskaya, N. G., Grivennikov, I. A., & Dolotov, O. V. (2024). Antidepressant-like and antistress effects of the ACTH(4-10) synthetic analogues Semax and Melanotan II on male rats in a model of chronic unpredictable stress. European Journal of Pharmacology, 984, 177068. https://doi.org/10.1016/j.ejphar.2024.177068
[4] Lebedeva, I. S., Panikratova, Ya. R., Sokolov, O. Yu., Kupriyanov, D. A., Rumshiskaya, A. D., Kost, N. V., & Myasoedov, N. F. (2018). Effects of Semax on the default mode network of the brain. Bulletin of Experimental Biology and Medicine, 165(5), 653–656. https://doi.org/10.1007/s10517-018-4234-3
[5] Shypshyna, M. S., Veselovsky, N. S., Myasoedov, N. F., Shram, S. I., & Fedulova, S. A. (2015). Effect of peptide Semax on synaptic activity and short-term plasticity of glutamatergic synapses of co-cultured dorsal root ganglion and dorsal horn neurons. Physiological Journal, 61(4), 48–55. https://doi.org/10.15407/fz61.04.048
[6] Arushanian, E. B., & Popov, A. V. (2008). Chronotropic activity of semax. Experimental and Clinical Pharmacology, 71(2), 14–16. PMID: 18488900 https://europepmc.org/article/med/18488900
[7] Arushanian, E. B., & Popov, A. V. (2009). Effect of semax on heart rate variability in various daytime periods. Experimental and Clinical Pharmacology, 72(2), 32–34. PMID: 19441725 https://pubmed.ncbi.nlm.nih.gov/19441725/
Levitskaia, N. G., Sebentsova, E. A., Andreeva, L. A., Alfeeva, L. Yu., Kamenskiĭ, A. A., & Miasoedov, N. F. (2010). Influence of Semax on the emotional state of white rats in the norm and against the background of cholecystokinin-tetrapeptide action. News of the Academy of Sciences, Biological Series, (2), 231–237. PMID: 20387390
[9] Eremin, K. O., Saransaari, P., Oja, S., & Raevskiĭ, K. S. (2004). Semax potentiates effects of D-amphetamine on the level of extracellular dopamine in the Sprague-Dawley rat striatum and on the locomotor activity of C57BL/6 mice. Experimental and Clinical Pharmacology, 67(2), 8–11. PMID: 15188751
Kolbaev, S. N., Sharonova, I. N., & Skrebitsky, V. G. (2025). The effect of peptide Semax, an ACTH(4-10) analogue, on intracellular calcium dynamics in rat brain neurons. Bulletin of Experimental Biology and Medicine, 179(4), 416–420. https://doi.org/10.1007/s10517-025-06501-z
Gusev, E. I., Skvortsova, V. I., Miasoedov, N. F., Nezavibat’ko, V. N., Zhuravleva, E. Yu., & Vanichkin, A. V. (1997). Effectiveness of semax in the acute period of hemispheric ischaemic stroke. Journal of Neurology and Psychiatry named after S.S. Korsakov, 97(6), 26–34. PMID: 11517472
[12] Gusev, E. I., Martynov, M. Yu., Kostenko, E. V., Petrova, L. V., & Bobyreva, S. N. (2018). The efficacy of semax in the treatment of patients at different stages of ischaemic stroke. Journal of Neurology and Psychiatry named after S.S. Korsakov, 118(3), 61–68. https://doi.org/10.17116/jnevro20181183261-68
The influence of Selank on the level of cytokines under the conditions of „social‟ stress. Current Reviews in Clinical and Experimental Pharmacology, 16(2), 162-167. https://doi.org/10.2174/1574884715666200704152810
[14] Panikratova, Ya. R., Lebedeva, I. S., Sokolov, O. Yu., Rumshiskaya, A. D., Kupriyanov, D. A., Kost, N. V., & Myasoedov, N. F. (2020). Functional connectomic approach to studying Selank and Semax effects. Doklady Biological Sciences, 490(1), 9–11. https://doi.org/10.1134/S001249662001007X
[15] Svishcheva, M.V., Mishina, Ye.S., Medvedeva, O.A., Bobyntsev, I.I., Mukhina, A.Yu., Kalutskii, P.V., Andreeva, L.A., & Myasoedov, N.F. (2021). Morphofunctional state of the large intestine in rats under conditions of restraint stress and administration of peptide ACTH(4–7)-PGP (Semax). Bulletin of Experimental Biology and Medicine, 170(3), 384–388. https://doi.org/10.1007/s10517-021-05072-z